IDENTIFICATION OF NOVEL GENETIC RISK FACTORS FOR ALZHEIMER'S DISEASE (AD) AND FR

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 阿尔茨海默S病(AD)是最常见的痴呆症，在65岁及以上年龄组中的患病率估计在5%至10%之间，在85岁及以上年龄组中的患病率高达47%(Evans等人)。(1989年)。AD的病理特征包括神经原纤维缠结和老年斑(Hardy&Selko，2002)。对涉及的神经系统以及阿尔茨海默病的遗传学和生物化学有了更好的了解，导致了新的治疗方法。最近，与阿尔茨海默病不同的退行性痴呆越来越受到关注。这导致了对这些疾病的临床和神经病理表型的更好的描述。额颞性痴呆(FTD)一词用于描述一组具有相关临床和神经病理特征的非AD痴呆(McKhann，2001)。FTD病例可能占流行病学样本中神经退行性痴呆的5%至10%，在尸检病例中占9%至16%(Bird等人，2003年)，使其成为阿尔茨海默病背后的一个重要致病原因。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Alzheimer s Disease (AD) is the most common form of dementia with prevalence rates estimated between 5% and 10% in the age group 65 years and older and as high as 47% for those age 85 and older (Evans et al. 1989). Pathological hallmarks of AD include neurofibrillary tangles and senile plaques (Hardy & Selko, 2002). A better understanding of the neural systems involved as well as the genetics and biochemistry of AD, had led to novel therapies. More recently, increasing attention has been paid to degenerative dementias that are distinct from AD. This has led to a better characterization of the clinical and neuropathological phenotypes of these diseases. The term frontotemporal dementia (FTD) is used to describe a group of non-AD dementias with related clinical and neuropathological characteristics (McKhann, 2001). Cases of FTD may comprise between 5% and 10% of neurodegenerative demantias in epidemiological samples and between 9% and 16% in autopsy cases (Bird et al., 2003), making it a significant cause of morbidity behind AD.